HMED

Hansa Medical

Market Cap 7,869.6M

Hansa Medical är ett Lundabaserat bioteknikbolag som utvecklar immunomodulerande enzym för behandling av autoimmuna indikationer. Den ledande läkemedelskandidaten kallas IdeS och har visat sig klyva och inaktivera antikroppar snabbt och effektivt vilket ger den stor potential inom flera antikroppsmedierade indikationer. Utvecklingen riktas främst mot att möjliggöra transplantation för sensitiserade patienter och där man har erhållit särläkemedelsstatus (Orphan Drug Designation) i USA och Europa. En potentiellt registreringsgrundande fas II-studie startade i oktober 2016 inom njurtransplantation. Resultat väntas i mitten av 2018, vilket vid positivt utfall skulle möjliggöra att IdeS når marknad 2019. En studie inom anti-GBM pågår även och ytterligare studier planeras starta under 2017 inom både transplantation och autoimmuna indikationer.  I tidig utvecklingsfas finns även enzym med något annorlunda profil, som kan komplettera eller förbättra användningen av IdeS. Under projektnamnet NiceR utvecklas IgG-klyvande enzym som kan komma att möjliggöra upprepad behandling. Hansa har även utvecklat en diagnostisk metod för prediktion av svår blodförgiftning (sepsis). Produkten är licensierad till Axis-Shield Diagnostics och genererar i dagsläget minimi-royalties om cirka 2 miljoner kronor per år. Organisatoriskt ligger bolagets tyngdpunkt inom forskning och utveckling men bolaget har påbörjat uppbyggandet av en marknadsorganisation för att kunna kommersialisera IdeS i egen regi i USA och Europa. Då man riktar sig mot specialiserade indikationer så kan en förhållandevis liten försäljningskår användas. 

+ more

Redeye Research

Reports

Notes

Today
Day High
205.20
204.6
Day Low
202.60
Day Open
205.20
Prev Close
204.60
VWAP
203.4
Volume
59K
Turnover
12.004M
Top Broker
VWAP
210.2
Avg Volume
74K
Avg Turnover
15.602M
Top Brokers
AVA/MLI
VWAP
208.0
Avg Volume
75K
Avg Turnover
15.647M
Top Brokers
AVA/MLI
VWAP
212.1
Avg Volume
85K
Avg Turnover
18.057M
Top Brokers
AVA/ENS
52 week summary
Price Range
158.0
Last
290.0
Beta
N/A
Market Cap
7,869.6M
Total Return
16.9%
Trailing P/E
-44.1
Div Yield
0.0%
Shares Outstanding
38.5M
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -20.3%
Change 12 Months 12.0%
Volume Trend
Average Volume 10 vs 60 Days -27.0%
Price VS
52 Week High -29.4%
50 Day Moving Average -3.6%
200 Day moving Average -11.8%

Add article markers

Compare Hansa Medical to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2018-03-20 Source: Redeye
Major Owners Equity Votes
Nexttobe AB 17.4%
17.5%
Oppenheimer 3.7%
3.8%
Handelsbanken Fonder 3.5%
3.5%
Avanza Pension 3.4%
3.4%
Thomas Olausson 3.1%
3.2%
SEB S.A. Client Assets Ucits. 2.4%
2.5%
Gladiator 2.4%
2.5%
Norron Fonder 2.3%
2.4%
AFA Försäkring 2.2%
2.2%
Polar Capital 1.6%
1.6%
Last updated: 2018-05-24 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
0
1 Sales
-4,000
Last 24 weeks
0 Purchases
0
1 Sales
-4,000
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • -50.7%
  • -50.6%
  • -186.0%
  • -1,079.8%
  • -1,079.8%
  • -1,080.8%
  •  
  • -1.89
  • -1.89
  • 0.00
  •  
  • 35.1
  •  
  • -175.6
  • 0.0
  • 0.0
  • 0.0
  • -28.6
  • 2.7
  • 2.7
  • 0.0
  •  
  • 94.4%
  • 100.0%
  • -176
  • 29
  • 0.0
  • 2015
  •  
  •  
  • 176
  • 2
  • 0
  • 0
  • 178
  •  
  • 2
  • 0
  • 0
  • 0
  • 36
  • 0
  • 0
  • 46
  • 0
  • 224
  •  
  •  
  • 0
  • 1
  • 11
  • 13
  • 0
  • 0
  • 0
  • 13
  • 0
  • 0
  • 212
  • 0
  • 212
  • 224
  • 2015
  • 6
  • -72
  • 0
  • -66
  • 0
  • -66
  • 0
  • -66
  • 7
  • 0
  • -59
  • 2015 Q2
  • 1
  • -23
  • -22
  • 0
  • 0
  • 0
  • -22
  • 0
  • 0
  • 0
  • -23
  • 0
  • -23
  • 2015 Q3
  • 1
  • -14
  • -14
  • 0
  • 0
  • 0
  • -14
  • 0
  • 0
  • 0
  • -14
  • 0
  • -14
  • 2015 Q4
  • 1
  • -20
  • -19
  • 0
  • 0
  • 0
  • -19
  • 0
  • 0
  • 0
  • -19
  • 0
  • -19
  • 2016
  •  
  • -44.9%
  • -44.8%
  • -387.8%
  • -5,121.5%
  • -5,121.5%
  • -5,121.2%
  •  
  • -2.94
  • -2.94
  • 0.00
  •  
  • 37.8
  •  
  • -253.0
  • 0.0
  • 0.0
  • 0.0
  • -116.6
  • 2.3
  • 2.3
  • 0.0
  •  
  • 91.3%
  • 100.0%
  • -253
  • 16
  • 0.0
  • 2016
  •  
  •  
  • 254
  • 3
  • 0
  • 1
  • 257
  •  
  • 3
  • 0
  • 0
  • 0
  • 37
  • 0
  • 0
  • 54
  • 0
  • 311
  •  
  •  
  • 0
  • 6
  • 19
  • 26
  • 1
  • 0
  • 0
  • 26
  • 1
  • 0
  • 284
  • 0
  • 284
  • 311
  • 2016
  • 2
  • -113
  • 0
  • -111
  • 0
  • -111
  • 0
  • -111
  • 12
  • -1
  • -99
  • 2016 Q1
  • 1
  • -20
  • -20
  • 0
  • 0
  • 0
  • -20
  • 0
  • 0
  • 0
  • -20
  • 0
  • -20
  • 2016 Q2
  • 1
  • -31
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • -31
  • 2016 Q3
  • 1
  • -27
  • -27
  • 0
  • 0
  • 0
  • -27
  • 0
  • 0
  • 0
  • -27
  • 0
  • -27
  • 2016 Q4
  • 1
  • -34
  • -34
  • 0
  • 0
  • 0
  • -34
  • 0
  • 0
  • 0
  • -34
  • 0
  • -34
  • 2017
  •  
  • -38.6%
  • -38.5%
  • -1,090.4%
  • -5,115.7%
  • -5,115.7%
  • -5,132.5%
  •  
  • -4.67
  • -4.67
  • 0.00
  •  
  • 37.8
  •  
  • -615.5
  • 0.0
  • 0.0
  • 0.0
  • -178.8
  • 3.5
  • 3.5
  • 0.0
  •  
  • 92.7%
  • 100.0%
  • -615
  • -3
  • 0.0
  • 2017
  •  
  •  
  • 616
  • 8
  • 0
  • 0
  • 624
  •  
  • 4
  • 0
  • 0
  • 0
  • 34
  • 0
  • 0
  • 56
  • 0
  • 680
  •  
  •  
  • 0
  • 4
  • 40
  • 44
  • 1
  • 0
  • 0
  • 44
  • 1
  • 5
  • 631
  • 0
  • 631
  • 680
  • 2017
  • 3
  • -180
  • 0
  • -176
  • 0
  • -176
  • 0
  • -176
  • 13
  • 1
  • -157
  • 2017 Q1
  • 1
  • -46
  • -45
  • 0
  • 0
  • 0
  • -45
  • 0
  • 0
  • 0
  • -45
  • 0
  • -45
  • 2017 Q2
  • 1
  • -46
  • -45
  • 0
  • 0
  • 0
  • -45
  • 0
  • 0
  • 0
  • -45
  • 0
  • -45
  • 2017 Q3
  • 1
  • -38
  • -37
  • 0
  • 0
  • 0
  • -37
  • 0
  • 0
  • 0
  • -38
  • 0
  • -38
  • 2017 Q4
  • 1
  • -50
  • -49
  • 0
  • 0
  • 0
  • -49
  • 0
  • 0
  • 0
  • -49
  • 0
  • -49
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1 E
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 Q1 E
  • 2020 Q2 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-06-12 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.